GPI-01
Introduction to Pharmacology — Drug Sources, Nomenclature, Development, and Routes of Administration
GPI-02
Pharmacokinetics — Absorption, Distribution, Metabolism, Elimination, and Half-Life
GPI-03
Pharmacodynamics — Receptor Types, Agonists and Antagonists, Dose-Response, and Therapeutic Index
GPI-04
Adverse Drug Effects and Drug Interactions — ADR Classification, Pharmacokinetic and Pharmacodynamic Interactions
GPI-05
Pharmacogenomics — Metabolizer Phenotypes, CYP Polymorphisms, HLA Associations, and Clinical Implementation
GPI-06
Clinical Pharmacology — Drug Development, Rational Prescribing, Special Populations, and Evidence-Based Practice
PK-01
Absorption and Bioavailability — Membrane Permeability, Routes of Administration, First-Pass Metabolism, and Oral Bioavailability
PK-02
Distribution — Volume of Distribution, Plasma Protein Binding, Tissue Barriers, and Compartment Models
PK-03
Metabolism — Phase I and II Reactions, CYP450 Isoforms, Hepatic Clearance, Enzyme Induction and Inhibition, and Prodrug Activation
PK-04
Elimination — Renal Drug Elimination, Tubular Secretion and Reabsorption, GFR-Based Dose Adjustment, Biliary Excretion, and Enterohepatic Recirculation
PK-05
PK Principles and Clinical Applications — Half-Life, Clearance, Steady State, Nonlinear Pharmacokinetics, Therapeutic Drug Monitoring, Special Populations, and PK–PD Relationships
PD-01
Drug–Receptor Interactions and Receptor Theory — Binding Kinetics, Agonism, Antagonism, Receptor Families, and Signal Transduction Overview
PD-02
Signal Transduction and Receptor Regulation — G Protein Pathways, Enzyme-Linked Receptors, Ion Channels, Nuclear Receptors, Desensitization, and Downregulation
PD-03
Quantitative Pharmacodynamics and Drug Interactions — Therapeutic Index, Drug Combinations, Isobolographic Analysis, Pharmacodynamic Interactions, Tolerance, and Tachyphylaxis
PD-04
Clinical Pharmacodynamics: Variability, PK/PD Integration, and Special Populations — Pharmacogenomics, PK/PD Modeling, Antimicrobial Indices, Placebo and Nocebo Effects, and TDM
ANS-intro-01
Autonomic Nervous System Organization and Functional Anatomy
ANS-intro-02
Neurotransmitter Synthesis, Release, and Inactivation
ANS-intro-03
Autonomic Receptors: Classification, Signaling, and Tissue Distribution
ANS-intro-04
Autonomic Drug Classes, Integration, and Clinical Applications
Adrenergic-01
Adrenergic Receptors — Subtypes, Signaling, and Tissue Distribution
Adrenergic-02
Catecholamine Agonists — Epinephrine, Norepinephrine, Dopamine, and Dobutamine
Adrenergic-03
Synthetic Adrenergic Agonists — Selectivity, ADME, and Clinical Applications
Adrenergic-04
Alpha-Adrenergic Antagonists — Classification, Pharmacology, and Clinical Applications
Adrenergic-05
Beta-Adrenergic Antagonists — Classification, Pharmacology, and Clinical Applications
Adrenergic-06
Indirect-Acting Adrenergic Agents, Neuron Blockers, and Integrated Adrenergic Pharmacology
Cholin-01
Cholinergic Receptors and Acetylcholine Neurotransmission
Cholin-02
Muscarinic Agonists and Acetylcholinesterase Inhibitors
Cholin-03
Irreversible AChE Inhibitors, Organophosphate Toxicology, and Cholinergic Toxidrome Management
Cholin-04
Muscarinic Antagonists: Pharmacology and Clinical Applications
HTN-01
Definition, Classification & Pathophysiology
HTN-02
Diagnosis, Evaluation & Secondary Causes
HTN-03
ACE Inhibitors & Angiotensin Receptor Blockers
HTN-04
Calcium Channel Blockers & Diuretics
HTN-05
Beta-Blockers, Alpha-Blockers, Centrally Acting Agents & Vasodilators
HTN-06
Treatment Strategy, Combination Therapy & Resistant Hypertension
HTN-07
Hypertension in Chronic Kidney Disease
HTN-08
Hypertension in Diabetes
HTN-09
Hypertension in Pregnancy
HTN-10
Hypertension in the Elderly & Isolated Systolic Hypertension
HTN-11
Hypertension with Comorbid Cardiovascular Disease
ARR-01
Cardiac Electrophysiology & the Vaughan Williams Classification
ARR-02
Class I Sodium Channel Blockers
ARR-03
Beta-Blockers as Antiarrhythmic Agents
ARR-04
Class III Potassium Channel Blockers
ARR-05
Calcium Channel Blockers & Miscellaneous Antiarrhythmic Agents
ARR-06
Atrial Fibrillation: Rate Control, Rhythm Control & Cardioversion
ARR-07
Ventricular Tachyarrhythmias & Sudden Cardiac Death Prevention
ARR-08
Bradyarrhythmias & Pacemaker Pharmacology
ARR-09
Special Populations & Emerging Antiarrhythmic Therapies
ANG-01
Nitrates — Mechanisms, Pharmacokinetics & Clinical Use
ANG-02
Beta-Blockers in Angina — Mechanisms, Evidence & Clinical Use
ANG-03
Beta-Blockers in Angina — Side Effects, Interactions & Special Populations
ANG-04
Calcium Channel Blockers in Angina
ANG-05
Ranolazine, Ivabradine, Nicorandil & Trimetazidine
ANG-06
Drug Selection, Escalation & Special Populations
ANG-07
Cardioprotective Background Therapy — Antiplatelet Agents, Statins & RAS Inhibitors
CHF-01
Heart Failure — Pathophysiology, Classification & Neurohormonal Basis of Therapy
CHF-02
ACE Inhibitors, ARBs & Angiotensin Receptor–Neprilysin Inhibitors (ARNI)
CHF-03
Beta-Blockers in Heart Failure — Reverse Remodeling & Landmark Trials
CHF-04
Diuretics & Aldosterone Antagonists in Heart Failure
CHF-05
SGLT2 Inhibitors, Ivabradine, Hydralazine/ISDN & Vericiguat
CHF-06
Digoxin, Inotropes & Vasopressors in Advanced Heart Failure
CHF-07
HFpEF, Device Therapy Interface & Heart Failure in Special Populations
LD-01
Lipids, Lipoproteins & Cardiovascular Risk
LD-02
Statins: Mechanisms, Pharmacology & Clinical Evidence
LD-03
Statins: Adverse Effects, Monitoring & Special Populations
LD-04
Ezetimibe & PCSK9 Inhibitors
LD-05
Fibrates, Niacin, Bile Acid Sequestrants & Omega-3 Fatty Acids
LD-06
Lipid Management in Special Cardiovascular Populations
CNS-01
Benzodiazepines — Mechanisms, Pharmacokinetics & Clinical Use
CNS-02
Z-Drugs, Orexin Receptor Antagonists & Melatonin Receptor Agonists
CNS-03
Barbiturates, IV Anesthetic Sedatives & Sedating Antidepressants
CNS-04
Toxicology, Dependence & Clinical Management of the Sedative-Hypnotic Class
CNS-05
Sleep Neurobiology, Comparative Pharmacology & Insomnia Management
CNS-06
Special Populations & Clinical Management Across the Lifespan
CNS-Opioid-01
Opioid Receptors, Endogenous Ligands & Signal Transduction
CNS-Opioid-02
Opioid Analgesics — Drug Profiles, Pharmacokinetics & Equianalgesic Dosing
CNS-Opioid-03
Adverse Effects, Toxicology & Naloxone Reversal
CNS-Opioid-04
Clinical Applications, Special Populations & Opioid Stewardship
CNS-Opioid-05
Neuropathic Pain, Integrative Case Reasoning & Individualized Opioid Selection
CNS-GA-01
Principles of General Anesthesia & Inhalational Agent Pharmacokinetics
CNS-GA-02
Pharmacology of Individual Inhalational Agents
CNS-GA-03
CNS and Cardiovascular Effects of Inhalational Anesthetics
CNS-GA-04
Pulmonary, Hepatic, Renal, Skeletal Muscle & Obstetrical Effects
CNS-GA-05
Intravenous Anesthetic Agents and Total Intravenous Anesthesia
CNS-LA-01
Mechanisms of Action & Physicochemical Pharmacology
CNS-LA-02
Individual Agents: Pharmacologic Profiles & Clinical Characteristics
CNS-LA-03
Routes of Administration & Clinical Applications
CNS-LA-04
Toxicity, Adverse Effects & Special Populations
CNS-LA-05
Neuraxial & Continuous Catheter Techniques
CNS-Antipsy-01
Dopamine Pharmacology, Pathways & Classification
CNS-Antipsy-02
First-Generation Antipsychotics
CNS-Antipsy-03
Second-Generation Antipsychotics: Core Agents
CNS-Antipsy-04
Newer Second-Generation Antipsychotics
CNS-Antipsy-05
Adverse Effects and Systematic Clinical Management
CNS-Antipsy-06
Clinical Pharmacology, Special Populations & Treatment Algorithms
CNS-AntiD-01
Neurobiology of Depression
CNS-AntiD-02
Selective Serotonin Reuptake Inhibitors
CNS-AntiD-03
SNRIs, Mirtazapine, and Bupropion
CNS-AntiD-04
Tricyclic Antidepressants and MAOIs
CNS-AntiD-05
Newer Oral Antidepressants with Novel Receptor Mechanisms
CNS-AntiD-06
Ketamine and Esketamine: Rapid-Acting Antidepressant Pharmacology
CNS-AntiD-07
Adverse Effects, Drug Interactions, and Special Populations
CNS-AntiD-08
Clinical Pharmacology: Treatment Algorithms, Augmentation, and TRD
CNS-Park-01
Pathophysiology of Parkinson's Disease & Overview of Drug Targets
CNS-Park-02
Levodopa and Carbidopa: Pharmacology and Clinical Use
CNS-Park-03
Dopamine Agonists
CNS-Park-04
MAO-B Inhibitors
CNS-Park-05
COMT Inhibitors
CNS-Park-06
Anticholinergics, Amantadine ER, and Adjunct Pharmacology
CNS-Park-07
Non-Motor Symptoms: Pharmacological Management
CNS-Park-08
Drug-Induced Parkinsonism, Special Populations, and Integrated Practice
CNS-Seiz-01
Pathophysiology of Seizures and Classification Framework
CNS-Seiz-02
Sodium Channel-Blocking Anti-Seizure Drugs
CNS-Seiz-03
GABAergic Anti-Seizure Drugs
CNS-Seiz-04
Broad-Spectrum Anti-Seizure Drugs: Valproate, Lamotrigine, and Topiramate
CNS-Seiz-05
Newer Anti-Seizure Agents: Levetiracetam, Lacosamide, and Brivaracetam
CNS-Seiz-06
Special Populations: Pediatrics, Pregnancy, and the Elderly
CNS-Seiz-07
Drug-Resistant Epilepsy: Mechanisms, Evaluation, and Management
NMJ-01
NMJ Physiology and Pharmacological Basis of Blockade
NMJ-02
Depolarizing and Non-Depolarizing Neuromuscular Blocking Agents
NMJ-03
Drug Interactions, Special Populations, and Adverse Effects
NMJ-04
Reversal of Neuromuscular Block and ICU Applications
HistBrad-01
Histamine: Synthesis, Receptors, and the H1 Response
HistBrad-02
H1 Antihistamines: First and Second Generation, ADME, and Drug Interactions
HistBrad-03
H2 Antagonists, Mast Cell Stabilizers, and Bradykinin Physiology
HistBrad-04
Bradykinin Clinical Pharmacology: HAE Therapeutics, Neprilysin Inhibition, and Emerging Targets
Sero-01
Serotonin Synthesis, Storage, Metabolism, and Receptor Pharmacology
Sero-02
CNS Serotonergic Pathways and SSRI/SNRI Pharmacology
Sero-03
Serotonin Syndrome, MAOIs, Triptans, and Other Serotonergic Agents
Sero-04
Serotonin in the GI Tract, Carcinoid Disease, and Emerging Pharmacology
Ergot-01
Ergot Alkaloid Chemistry, Receptor Pharmacology, and Vasoactive Mechanisms
Ergot-02
Ergotamine and DHE in Migraine Management
Ergot-03
Dopaminergic Ergot Derivatives: Bromocriptine, Cabergoline, and Pergolide
Ergot-04
Uterotonic Ergot Alkaloids: Methylergonovine, Ergometrine, and Obstetric Applications
Ergot-05
Methysergide, Ergot Toxicity Syndromes, and CYP3A4 Interaction Pharmacology
PEP-01
RAAS, ACE Inhibitors, and Direct Renin Inhibitors
PEP-02
ARBs, Sacubitril-Valsartan, and the Natriuretic Peptide System
PEP-03
Endothelin Pharmacology and Endothelin Receptor Antagonists in PAH
PEP-04
Vasopressin Pharmacology and Vaptans
PEP-05
CGRP Pharmacology and Migraine Preventive Therapeutics
PEP-06
Natriuretic Peptides in Heart Failure, NK1 Antagonists, and Integrative Framework
Pulm-01
Bronchodilators: Beta-2 Agonists and Anticholinergic Agents
Pulm-02
Inhaled Corticosteroids, Methylxanthines, and Anti-Leukotriene Agents
Pulm-03
Pharmacology of COPD: Triple Therapy, Exacerbation Management, and Mucolytics
Pulm-04
Biologic Agents in Severe Asthma: Anti-IgE, Anti-IL-5, and Anti-IL-4R Therapy
Pulm-05
Pulmonary Hypertension Pharmacology: Prostacyclins, ERAs, PDE-5 Inhibitors, and sGC Stimulators
Pulm-06
Cystic Fibrosis CFTR Modulator Pharmacology: Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor Triple Therapy
Pulm-07
Pharmacology of Respiratory Failure and Mechanical Ventilation Support
Renal-01
Diuretic Pharmacology, Part 1: Loop Diuretics and Thiazides
Renal-02
Diuretic Pharmacology, Part 2: Potassium-Sparing Diuretics, Carbonic Anhydrase Inhibitors, Osmotic Agents, and Vasopressin Antagonists
Renal-03
Chronic Kidney Disease Pharmacology: Progression, Anemia, and Mineral Metabolism
Renal-04
Renal Transplant Immunosuppression Pharmacology
Renal-05
Fluid, Acid-Base, and Electrolyte Emergencies
Gastro-01
Acid Suppression and Peptic Ulcer Disease
Gastro-02
Motility Pharmacology: Prokinetics and Antiemetics
Gastro-03
IBD Part 1: Aminosalicylates, Corticosteroids, and Immunomodulators
Gastro-04
IBD Part 2: Biologics and Small Molecules
Gastro-05
Lower GI: Constipation, Diarrhea, and IBS Pharmacotherapy
Gastro-06
Liver Part 1: Viral Hepatitis and Acute Liver Failure
Gastro-07
Liver Part 2: ALD, MASLD/MASH, Cholestatic Disease, and Hepatic Encephalopathy
Gastro-08
Pancreatic and Nutritional Pharmacology
Cort-01
Steroid Biochemistry, Glucocorticoid Receptor Mechanisms, and Pharmacokinetics
Cort-02
Glucocorticoid Clinical Pharmacology: Immunosuppression and Organ-Specific Applications
Cort-03
Adverse Effects, Drug Interactions, and Glucocorticoid-Induced Osteoporosis Management
Cort-04
Mineralocorticoid Pharmacology, Adrenal Insufficiency, Congenital Adrenal Hyperplasia, and Cushing Syndrome Management
Diab-01
Insulin Pharmacology: Structure, Formulations, Pharmacokinetics, and Clinical Use
Diab-02
Sulfonylureas and Meglitinides: Insulin Secretagogues in Clinical Practice
Diab-03
Metformin, DPP-4 Inhibitors, and Thiazolidinediones: Non-Secretagogue Oral Agents
Diab-04
GLP-1 Receptor Agonists: Mechanisms, Cardiovascular Outcomes, and Clinical Use
Diab-05
GLP-1/GIP Dual Agonism, Weight Pharmacology, and Emerging Agents
Diab-06
SGLT-2 Inhibitors: Transporter Biology, Cardiovascular and Renal Outcome Trials, and Safety
Diab-07
Special Clinical Contexts: T2DM with ASCVD, CKD, Heart Failure, Pregnancy, and Elderly
Thy-01
Thyroid Hormone Physiology and Pharmacokinetics
Thy-02
Hypothyroidism: Clinical Pharmacology and Management
Thy-03
Hyperthyroidism: Thionamides, Adjuncts, and Thyroid Storm
Thy-04
Radioiodine, Thyroid Cancer Pharmacotherapy, and Special Contexts
Ova-01
Estrogen and Progestin Pharmacology
Ova-02
Hormonal Contraception
Ova-03
Hormone Therapy, SERMs, and GnRH Modulators
Ova-04
Ovulation Induction, ART Pharmacology, and Ovarian Hyperstimulation
Ova-05
Androgen Pharmacology
Hypothal-01
Hypothalamic Hormones and Their Pharmacological Analogs
Hypothal-02
GnRH Analogs in Clinical Practice
Hypothal-03
Growth Hormone Axis Pharmacology
Hypothal-04
Pituitary Adenoma Pharmacotherapy
ACD1-01
Principles of Cancer Pharmacology
ACD1-02
Alkylating Agents
ACD1-04
Topoisomerase Inhibitors and Antitumor Antibiotics
ACD1-05
Antimicrotubule Agents
ACD1-06
Miscellaneous Cytotoxics, Drug Interactions, and Supportive Pharmacology
ACD2-01
BCR-ABL, EGFR, and ALK/ROS1 Kinase Inhibitors
ACD2-02
Targeted Small Molecule Inhibitors: BRAF/MEK, CDK4/6, PI3K/mTOR, BTK, BCL-2, PARP, FLT3/IDH, and Proteasome
ACD2-03
Monoclonal Antibodies and Antibody-Drug Conjugates
ACD2-04
Immune Checkpoint Inhibitors and Hormonal Oncology
AntiB-01
Beta-Lactam Antibiotics: Penicillins
AntiB-02
Beta-Lactam Antibiotics: Cephalosporins
AntiB-03
Beta-Lactam Antibiotics: Carbapenems, Monobactams & Beta-Lactamase Inhibitors
AntiB-05
Fluoroquinolones
AntiB-06
Macrolides, Tetracyclines & Glycylcyclines
AntiB-07
Glycopeptides & Lipopeptides
AntiB-08
Oxazolidinones, Streptogramins & Miscellaneous Gram-Positive Agents
AntiB-09
Sulfonamides, Trimethoprim & Nitrofurantoin
AntiB-10
Metronidazole, Clindamycin & Miscellaneous Agents
AntiB-11
Bacterial Resistance Mechanisms
AntiB-12
Drug Interactions, Adverse Effects & Special Populations
Viral-01
HIV — NRTIs, NNRTIs, and the Reverse Transcriptase Target
Viral-02
HIV — Protease Inhibitors, Integrase Inhibitors, and Entry Inhibitors
Viral-03
Antiretroviral Interactions, Toxicity, and Special Populations
Viral-04
Hepatitis B and Hepatitis C Pharmacology
Viral-05
Herpesvirus Pharmacology
Viral-06
Influenza and Respiratory Virus Pharmacology
Viral-07
Opportunistic Viral Infections in Immunocompromised Hosts
Viral-08
Antiviral Resistance Principles
Fung-01
Polyene Antifungals — Amphotericin B Formulations and Nystatin
Fung-02
Azole Antifungals — Fluconazole and Itraconazole
Fung-03
Extended-Spectrum Azoles — Voriconazole, Posaconazole, and Isavuconazole
Fung-04
Echinocandins — Caspofungin, Micafungin, and Anidulafungin
Fung-05
Antifungal Drug Interactions and Therapeutic Drug Monitoring
Fung-06
Allylamines, Flucytosine, and Griseofulvin
Fung-07
Clinical Syndromes — Candidiasis, Aspergillosis, Cryptococcosis, Mucormycosis, and Endemic Mycoses
AntiPara-01
Antimalarial Agents — Quinolines, Artemisinins, and Prophylaxis
AntiPara-02
Antiprotozoal Agents (Non-Malarial) — Metronidazole, Trypanosomiasis, Leishmaniasis, and Toxoplasmosis
AntiPara-03
Antihelminthic Agents — Benzimidazoles, Ivermectin, Praziquantel, and Tissue Invasion
AntiPara-04
Ectoparasiticides and Special Populations — Scabies, Pediculosis, Pregnancy, and Drug Interactions
Coag-01
Coagulation Cascade, Hemostatic Targets, and Overview of Antithrombotic Pharmacology
Coag-02
Heparins and Indirect Thrombin Inhibitors
Coag-03
Vitamin K Antagonists — Warfarin Pharmacology and Clinical Management
Coag-04
Direct Oral Anticoagulants — Dabigatran, Rivaroxaban, Apixaban, and Edoxaban
Coag-05
Antiplatelet Therapy: From Aspirin to Novel Agents
Coag-06
Thrombolytic Therapy and Procoagulant Agents
Immuno-01
Foundations of Immunopharmacology — Immune Cells, Cytokines, and Drug Targets
Immuno-02
Transplant Immunosuppression — Calcineurin Inhibitors, mTOR Inhibitors, and Induction Agents
Immuno-03
Biologic Immunosuppressants — TNF Inhibitors, Interleukin Antagonists, and B-Cell Therapies
Immuno-04
JAK Inhibitors and Targeted Small-Molecule Immunosuppressants
Immuno-05
Complement Pharmacology, IVIG, and Emerging Immunological Targets
Anti_inflam-01
NSAIDs — Mechanisms, Pharmacokinetics, and COX Selectivity
Anti_inflam-02
NSAID Toxicity, Drug Interactions, and Special Populations
Anti_inflam-03
Corticosteroids — Mechanisms, Pharmacology, and Clinical Use
Anti_inflam-04
Corticosteroid Toxicity, Drug Interactions, and Gout Pharmacology